In a groundbreaking achievement, scientists have developed a novel anti-viral therapy that targets the HIV’s protective shield, known as the HIV capsid. This innovative drug, called lenacapavir, marks the first time a medication has been designed to directly attack the HIV capsid, disrupting the virus’ life cycle and potentially halting its spread.
HIV, or human immunodeficiency virus, is a formidable adversary that weakens the body’s immune system by attacking essential CD4+ T cells. Over time, if left untreated, HIV infection can progress to AIDS, leaving the individual vulnerable to severe infections and diseases. Despite significant advancements in HIV treatments over the years, the quest for a cure continues due to the virus’ ability to mutate rapidly and evade the host’s immune defenses.
Lenacapavir offers a promising solution by targeting the HIV capsid, a protein shell responsible for protecting the viral genome during infection and replication. By inhibiting the function of this protective armor, lenacapavir effectively interrupts the HIV life cycle, preventing further damage to the immune system.